OBJECTIVES: The aim of this study was to compare plasma biomarkers of coagulation between HIV-infected individuals and HIV-uninfected controls and to assess the impact of disturbances in coagulation on neurocognitive functioning in HIV. DESIGN: A cross-sectional study of 66 antiretroviral therapy treated, virally suppressed, HIV-infected and 34 HIV-uninfected older (≥50 years of age) adults. METHODS: Participants completed standardized neurobehavioral and neuromedical assessments. Neurocognitive functioning was evaluated using a well validated comprehensive neuropsychological battery. Plasma biomarkers associated with procoagulation (fibrinogen, p-selectin, tissue factor and von Willebrand factor), anticoagulation (antithrombin, protein C and thrombomodulin), fibrinolysis (d-dimer, plasminogen activator inhibitor-1 and plasminogen) were collected. Multivariable linear regression was used to test the interaction of HIV and coagulation on neurocognitive functioning. RESULTS: Most participants were male (78.0%) and non-Hispanic white (73.0%) with a mean age of 57.8 years. Among HIV-infected participants, mean estimated duration of HIV infection was 19.4 years and median current CD4 cell count was 654 cells/μl. Levels of soluble biomarkers of procoagulation, anticoagulation and fibrinolysis were comparable between the HIV serostatus groups. Coagulation and HIV had an interacting effect on neurocognitive functioning, such that greater coagulation imbalance was associated with poorer neurocognitive functioning among the HIV-infected participants. The moderating effect of coagulation on neurocognition was driven by procoagulant but not anticoagulant or fibrinolytic biomarkers. CONCLUSIONS: Elevated levels of procoagulants may exert a particularly detrimental effect on neurocognitive functioning among older HIV-infected persons. A better understanding of the specific role of coagulation in the cause of HIV-associated neurocognitive disorders may lead to treatments aimed at reducing coagulopathy, thereby improving neurocognitive outcomes.
OBJECTIVES: The aim of this study was to compare plasma biomarkers of coagulation between HIV-infected individuals and HIV-uninfected controls and to assess the impact of disturbances in coagulation on neurocognitive functioning in HIV. DESIGN: A cross-sectional study of 66 antiretroviral therapy treated, virally suppressed, HIV-infected and 34 HIV-uninfected older (≥50 years of age) adults. METHODS:Participants completed standardized neurobehavioral and neuromedical assessments. Neurocognitive functioning was evaluated using a well validated comprehensive neuropsychological battery. Plasma biomarkers associated with procoagulation (fibrinogen, p-selectin, tissue factor and von Willebrand factor), anticoagulation (antithrombin, protein C and thrombomodulin), fibrinolysis (d-dimer, plasminogen activator inhibitor-1 and plasminogen) were collected. Multivariable linear regression was used to test the interaction of HIV and coagulation on neurocognitive functioning. RESULTS: Most participants were male (78.0%) and non-Hispanic white (73.0%) with a mean age of 57.8 years. Among HIV-infectedparticipants, mean estimated duration of HIV infection was 19.4 years and median current CD4 cell count was 654 cells/μl. Levels of soluble biomarkers of procoagulation, anticoagulation and fibrinolysis were comparable between the HIV serostatus groups. Coagulation and HIV had an interacting effect on neurocognitive functioning, such that greater coagulation imbalance was associated with poorer neurocognitive functioning among the HIV-infectedparticipants. The moderating effect of coagulation on neurocognition was driven by procoagulant but not anticoagulant or fibrinolytic biomarkers. CONCLUSIONS: Elevated levels of procoagulants may exert a particularly detrimental effect on neurocognitive functioning among older HIV-infectedpersons. A better understanding of the specific role of coagulation in the cause of HIV-associated neurocognitive disorders may lead to treatments aimed at reducing coagulopathy, thereby improving neurocognitive outcomes.
Authors: M Cherner; P Suarez; D Lazzaretto; L Artiola I Fortuny; Monica Rivera Mindt; S Dawes; Thomas Marcotte; I Grant; R Heaton Journal: Arch Clin Neuropsychol Date: 2007-02-12 Impact factor: 2.813
Authors: Ahamad Hassan; Beverley J Hunt; Michael O'Sullivan; Kiran Parmar; John M Bamford; Dennis Briley; Martin M Brown; Dafydd J Thomas; Hugh S Markus Journal: Brain Date: 2003-02 Impact factor: 13.501
Authors: Jessica Foley; Mark Ettenhofer; Matthew J Wright; Iraj Siddiqi; Melissa Choi; April D Thames; Karen Mason; Steven Castellon; Charles H Hinkin Journal: Clin Neuropsychol Date: 2010-02 Impact factor: 3.535
Authors: Mark A Wallet; Thomas W Buford; Anna-Maria Joseph; Madhuri Sankuratri; Christiaan Leeuwenburgh; Marco Pahor; Todd Manini; John W Sleasman; Maureen M Goodenow Journal: BMC Immunol Date: 2015-07-24 Impact factor: 3.615
Authors: S Smieszek; P Jia; D C Samuels; Z Zhao; J Barnholtz-Sloan; H Kaur; S Letendre; R Ellis; D R Franklin; T Hulgan; A Kallianpur; W S Bush Journal: Mitochondrion Date: 2018-07-17 Impact factor: 4.160
Authors: Deanna Saylor; Anupama Kumar; Gertrude Nakigozi; Aggrey Anok; James Batte; Alice Kisakye; Richard Mayanja; Noeline Nakasujja; Kevin R Robertson; Ronald H Gray; Maria J Wawer; Carlos A Pardo; Ned Sacktor Journal: J Neurovirol Date: 2019-06-04 Impact factor: 2.643
Authors: Jessica L Montoya; Laura M Campbell; Emily W Paolillo; Ronald J Ellis; Scott L Letendre; Dilip V Jeste; David J Moore Journal: J Acquir Immune Defic Syndr Date: 2019-01-01 Impact factor: 3.731
Authors: Anna C Belkina; Alina Starchenko; Katherine A Drake; Elizabeth A Proctor; Riley M F Pihl; Alex Olson; Douglas A Lauffenburger; Nina Lin; Jennifer E Snyder-Cappione Journal: Front Immunol Date: 2018-12-05 Impact factor: 8.786
Authors: Marilza Campos de Magalhães; Juan Camilo Sánchez-Arcila; Ana Carolina de Brito Lyra; Luiz Felipe Boufleur Long; Isabelle Vasconcellos de Souza; Fernando Raphael de Almeida Ferry; Adilson José de Almeida; Soniza Vieira Alves-Leon Journal: PLoS One Date: 2020-02-12 Impact factor: 3.240